Eli Lilly and Company - LLY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $559.08
Forecasted Upside: -5.41%
Number of Analysts: 21
Breakdown:
1 Sell Ratings
2 Hold Ratings
18 Buy Ratings
0 Strong Buy Ratings

^$591.04 As of 11/30/2023 01:00 AM ET

▼ -0.82 (-0.14%)

1 month | 3 months | 12 months

Get New Eli Lilly and Company Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

^$559.08

▼ -5.41% Downside Potential

This price target is based on 21 analysts offering 12 month price targets for Eli Lilly and Company in the last 3 months. The average price target is $559.08, with a high forecast of $722.00 and a low forecast of $278.00. The average price target represents a -5.41% upside from the last price of $591.04.

Current Consensus is Moderate Buy

The current consensus among 21 polled investment analysts is to moderate buy stock in Eli Lilly and Company. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

6/8/2022

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

9/6/2022

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

12/5/2022

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

3/5/2023

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

6/3/2023

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

9/1/2023

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

10/31/2023

0 strong buy ratings
18 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

11/30/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
11/29/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$650.00	Low
11/15/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
11/9/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$535.00	Low
11/8/2023	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low
11/3/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$673.00 ➝ $722.00	Low
10/23/2023	Citigroup	Boost Target	Buy ➝ Buy	$525.00 ➝ $675.00	Low
10/23/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
10/20/2023	UBS Group	Reiterated Rating	Buy ➝ Buy	$612.00 ➝ $710.00	Low
10/11/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$640.00 ➝ $673.00	Low
10/9/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
10/9/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$615.00 ➝ $650.00	Low
10/6/2023	Bank of America	Boost Target		$600.00 ➝ $700.00	Low
10/2/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
9/5/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
9/5/2023	Argus	Boost Target	Buy ➝ Buy	$470.00 ➝ $620.00	Low
9/5/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$617.00 ➝ $640.00	Low
8/22/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$630.00	Low
8/9/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$560.00 ➝ $617.00	Low
8/9/2023	The Goldman Sachs Group	Boost Target	Neutral ➝ Neutral	$385.00 ➝ $470.00	N/A
8/9/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$550.00	N/A
8/9/2023	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$565.00 ➝ $633.00	Low
8/9/2023	Truist Financial	Boost Target	Buy ➝ Buy	$525.00 ➝ $600.00	Low
8/9/2023	Barclays	Boost Target	Overweight ➝ Overweight	$500.00 ➝ $590.00	Low
8/9/2023	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$510.00 ➝ $600.00	Low
8/9/2023	Credit Suisse Group	Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	Low
8/9/2023	Bank of America	Boost Target		$500.00 ➝ $600.00	Low
8/8/2023	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$408.00 ➝ $615.00	Low
8/8/2023	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$490.00 ➝ $580.00	Low
8/8/2023	Cantor Fitzgerald	Boost Target		$550.00 ➝ $630.00	Low
8/8/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$500.00 ➝ $615.00	Low
7/28/2023	JPMorgan Chase & Co.	Boost Target	Overweight	$475.00 ➝ $510.00	Low
7/26/2023	Citigroup	Boost Target	Buy	$360.00 ➝ $525.00	Low
7/21/2023	Jefferies Financial Group	Boost Target	Hold	$408.00 ➝ $430.00	Low
7/21/2023	Morgan Stanley	Boost Target	Overweight	$551.00 ➝ $560.00	Low
7/20/2023	Truist Financial	Boost Target	Buy	$430.00 ➝ $525.00	Low
7/18/2023	BMO Capital Markets	Boost Target		$505.00 ➝ $565.00	Low
7/14/2023	HSBC	Initiated Coverage	Buy	$560.00	Low
6/27/2023	22nd Century Group	Reiterated Rating	Maintains		Low
6/27/2023	Cantor Fitzgerald	Boost Target		$485.00 ➝ $550.00	Low
6/27/2023	Barclays	Boost Target		$420.00 ➝ $500.00	Low
6/20/2023	Berenberg Bank	Boost Target		$375.00 ➝ $500.00	Low
5/26/2023	Wells Fargo & Company	Boost Target		$440.00 ➝ $500.00	Low
5/24/2023	UBS Group	Boost Target	Buy	$447.00 ➝ $498.00	Low
5/24/2023	Bank of America	Boost Target	Buy	$450.00 ➝ $500.00	Low
5/15/2023	Morgan Stanley	Boost Target		$478.00 ➝ $507.00	Low
5/4/2023	BMO Capital Markets	Boost Target		$430.00 ➝ $505.00	Low
5/4/2023	JPMorgan Chase & Co.	Boost Target		$430.00 ➝ $475.00	Low
5/4/2023	Credit Suisse Group	Boost Target		$420.00 ➝ $490.00	Low
5/1/2023	SVB Securities	Boost Target		$410.00 ➝ $458.00	Low
5/1/2023	Barclays	Boost Target		$400.00 ➝ $420.00	Low
4/28/2023	3M	Reiterated Rating	Maintains		Low
4/28/2023	Truist Financial	Boost Target		$421.00 ➝ $430.00	Low
4/28/2023	Cantor Fitzgerald	Boost Target		$432.00 ➝ $485.00	Low
4/28/2023	Credit Suisse Group	Boost Target		$400.00 ➝ $420.00	Low
4/28/2023	JPMorgan Chase & Co.	Boost Target		$400.00 ➝ $430.00	Low
4/28/2023	UBS Group	Boost Target		$438.00 ➝ $447.00	Low
4/28/2023	Wells Fargo & Company	Boost Target		$375.00 ➝ $440.00	Low
4/11/2023	Guggenheim	Lower Target	Buy	$395.00 ➝ $392.00	Low
4/10/2023	Morgan Stanley	Boost Target	Overweight	$444.00 ➝ $448.00	Low
4/3/2023	Jefferies Financial Group	Boost Target	Hold	$290.00 ➝ $310.00	Low
3/13/2023	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$360.00 ➝ $375.00	Low
3/6/2023	Jefferies Financial Group	Initiated Coverage	Hold	$290.00	Low
3/3/2023	Citigroup	Lower Target	Buy	$370.00 ➝ $360.00	Low
3/1/2023	Morgan Stanley	Lower Target	Overweight	$455.00 ➝ $444.00	Low
2/15/2023	Societe Generale	Downgrade	Hold ➝ Sell	$278.00	Low
2/3/2023	Wells Fargo & Company	Lower Target	Equal Weight	$375.00 ➝ $360.00	Low
2/3/2023	Morgan Stanley	Boost Target	Overweight	$440.00 ➝ $455.00	Low
1/3/2023	Barclays	Boost Target	Overweight	$395.00 ➝ $400.00	Low
12/16/2022	SVB Leerink	Boost Target	Outperform	$384.00 ➝ $410.00	Low
12/15/2022	UBS Group	Lower Target	Buy	$428.00 ➝ $420.00	Low
12/14/2022	Morgan Stanley	Lower Target	Overweight	$446.00 ➝ $440.00	Low
12/14/2022	JPMorgan Chase & Co.	Boost Target		$380.00 ➝ $400.00	Low
12/9/2022	UBS Group	Boost Target		$407.00 ➝ $428.00	Low
12/8/2022	Wells Fargo & Company	Boost Target	Equal Weight	$365.00 ➝ $375.00	Low
12/7/2022	Guggenheim	Boost Target	Buy	$399.00 ➝ $401.00	Low
12/6/2022	Credit Suisse Group	Boost Target	Outperform	$395.00 ➝ $400.00	Low
12/6/2022	Morgan Stanley	Boost Target	Overweight	$436.00 ➝ $446.00	Low
12/5/2022	Cowen	Boost Target	Outperform	$390.00 ➝ $430.00	Low
12/5/2022	Cowen	Boost Target		$390.00 ➝ $430.00	Low
11/22/2022	Berenberg Bank	Boost Target	Buy	$345.00 ➝ $375.00	Low
11/17/2022	Credit Suisse Group	Initiated Coverage	Outperform	$395.00	Low
11/17/2022	Morgan Stanley	Lower Target	Overweight	$441.00 ➝ $436.00	Low
11/15/2022	Truist Financial	Boost Target		$400.00 ➝ $421.00	Low
11/8/2022	The Goldman Sachs Group	Boost Target	Neutral	$281.00 ➝ $313.00	Low
11/2/2022	SVB Leerink	Boost Target	Outperform	$341.00 ➝ $384.00	Low
11/2/2022	Morgan Stanley	Boost Target	Overweight	$408.00 ➝ $441.00	Low
11/2/2022	Wells Fargo & Company	Boost Target	Equal Weight	$305.00 ➝ $365.00	Low
11/2/2022	Barclays	Boost Target	Overweight	$355.00 ➝ $395.00	Low
10/12/2022	Morgan Stanley	Lower Target	Overweight	$412.00 ➝ $408.00	Low
9/30/2022	Argus	Boost Target		$315.00 ➝ $360.00	Low
9/22/2022	UBS Group	Upgrade	Neutral ➝ Buy	$335.00 ➝ $363.00	Low
9/7/2022	Morgan Stanley	Boost Target	Overweight	$395.00 ➝ $412.00	Low
9/6/2022	BMO Capital Markets	Boost Target	Outperform	$369.00 ➝ $396.00	Low
8/25/2022	Citigroup	Boost Target		$285.00 ➝ $370.00	Low
7/27/2022	UBS Group	Boost Target	Outperform	$335.00	Low
7/8/2022	Morgan Stanley	Boost Target	Overweight	$369.00 ➝ $395.00	N/A
7/7/2022	Barclays	Boost Target	Overweight	$333.00 ➝ $355.00	N/A
6/1/2022	JPMorgan Chase & Co.	Boost Target		$340.00 ➝ $355.00	Low
5/23/2022	SVB Leerink	Initiated Coverage	Outperform	$341.00	Low
5/2/2022	Mizuho	Boost Target		$315.00 ➝ $356.00	Low
4/29/2022	Morgan Stanley	Boost Target		$364.00 ➝ $369.00	High
4/29/2022	Wells Fargo & Company	Boost Target		$280.00 ➝ $305.00	Medium
4/12/2022	The Goldman Sachs Group	Boost Target	Neutral	$234.00 ➝ $264.00	Low
4/6/2022	Morgan Stanley	Boost Target	Overweight	$265.00 ➝ $364.00	High
3/17/2022	Bank of America	Boost Target		$300.00 ➝ $315.00	Medium
3/10/2022	Daiwa Capital Markets	Initiated Coverage	Outperform	$286.00	Medium
2/4/2022	Mizuho	Lower Target	Buy	$302.00 ➝ $293.00	High
2/4/2022	Morgan Stanley	Lower Target	Overweight	$272.00 ➝ $265.00	Medium
1/24/2022	Morgan Stanley	Lower Target	Overweight	$275.00 ➝ $272.00	Low
1/21/2022	DZ Bank	Upgrade	Hold ➝ Buy	$291.00	Medium
1/5/2022	Mizuho	Boost Target		$272.00 ➝ $302.00	High
1/4/2022	Wells Fargo & Company	Boost Target	Equal Weight	$270.00 ➝ $280.00	Low
1/3/2022	Sanford C. Bernstein	Boost Target	Market Perform	$250.00 ➝ $300.00	High
12/20/2021	Berenberg Bank	Boost Target	Buy	$270.00 ➝ $305.00	High
12/20/2021	Barclays	Boost Target	Overweight	$280.00 ➝ $325.00	High
12/17/2021	The Goldman Sachs Group	Initiated Coverage	Neutral	$236.00	High
12/16/2021	Mizuho	Initiated Coverage	Buy	$272.00	Low
12/16/2021	BMO Capital Markets	Boost Target	Outperform	$311.00 ➝ $320.00	Low
12/16/2021	Bank of America	Boost Target	Buy	$285.00 ➝ $300.00	Low
12/16/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
12/8/2021	Wells Fargo & Company	Initiated Coverage	Equal Weight	$270.00	Low
11/24/2021	Truist Financial	Boost Target	Buy	$262.00 ➝ $301.00	Low
11/18/2021	BMO Capital Markets	Initiated Coverage	Outperform	$311.00	Medium
10/27/2021	Mizuho	Lower Target	Buy	$279.00 ➝ $272.00	Low
10/11/2021	Berenberg Bank	Upgrade	Hold ➝ Buy	$240.00 ➝ $270.00	Low
9/29/2021	Citigroup	Upgrade	Neutral ➝ Buy	$210.00 ➝ $265.00	High
9/24/2021	JPMorgan Chase & Co.	Reiterated Rating	Buy	$300.00	Low
8/30/2021	Cowen	Boost Target	Outperform	$250.00 ➝ $300.00	Low
8/9/2021	Argus	Boost Target	Buy	$225.00 ➝ $300.00	Medium
8/5/2021	DZ Bank	Upgrade	Hold ➝ Buy	$288.00	Low
8/4/2021	JPMorgan Chase & Co.	Boost Target	Top Pick ➝ Overweight	$270.00 ➝ $300.00	Medium
8/4/2021	Morgan Stanley	Boost Target	Overweight	$207.00 ➝ $275.00	High
8/4/2021	Mizuho	Boost Target	Buy	$250.00 ➝ $279.00	High
7/27/2021	Truist Financial	Initiated Coverage	Buy	$262.00	Low
7/7/2021	Mizuho	Reiterated Rating	Buy	$250.00	Low
7/6/2021	Barclays	Boost Target	Overweight	$227.00 ➝ $250.00	Low
7/2/2021	Truist Financial	Boost Target	Buy ➝ Buy	$225.00 ➝ $262.00	Low
6/24/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$245.00 ➝ $300.00	High
6/24/2021	Cowen	Boost Target	Positive ➝ Outperform	$235.00 ➝ $250.00	High
6/15/2021	JPMorgan Chase & Co.	Boost Target	Overweight	$240.00 ➝ $260.00	Low
6/14/2021	The Goldman Sachs Group	Boost Target	Positive ➝ Conviction-Buy	$252.00 ➝ $270.00	Low
6/8/2021	Truist Financial	Reiterated Rating	Buy	$225.00	Medium
4/28/2021	Morgan Stanley	Lower Target	Overweight	$217.00 ➝ $207.00	Medium
4/28/2021	Mizuho	Lower Target	Buy	$228.00 ➝ $216.00	Medium
4/28/2021	Barclays	Lower Target	Overweight	$232.00 ➝ $227.00	Medium
3/15/2021	Truist Financial	Boost Target	Buy	$215.00 ➝ $225.00	High
2/12/2021	Cowen	Boost Target	Outperform	$195.00 ➝ $235.00	Low
2/4/2021	Morgan Stanley	Boost Target	Overweight	$190.00 ➝ $217.00	Medium
2/1/2021	Truist Financial	Boost Target		$200.00 ➝ $215.00	Low
2/1/2021	Mizuho	Boost Target	Buy	$222.00 ➝ $228.00	Low
2/1/2021	Barclays	Boost Target	Overweight	$190.00 ➝ $232.00	Low
1/22/2021	Bank of America	Boost Target	Buy	$195.00 ➝ $225.00	Medium
1/19/2021	Mizuho	Upgrade	Neutral ➝ Buy	$164.00 ➝ $222.00	N/A
1/12/2021	Truist Financial	Boost Target		$182.00 ➝ $200.00	Medium
12/16/2020	Mizuho	Boost Target	Neutral	$156.00 ➝ $164.00	High
12/10/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$147.00 ➝ $183.00	Medium
11/17/2020	Mizuho	Lower Target	Neutral	$164.00 ➝ $156.00	Low
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Market Perform	$150.00	Low
10/28/2020	Morgan Stanley	Lower Target	Overweight	$176.00 ➝ $170.00	Low
10/23/2020	Truist Financial	Initiated Coverage	Buy	$180.00	Medium
10/16/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$190.00 ➝ $200.00	Low
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$144.00	Medium
9/3/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$149.55 ➝ $176.00	High
8/14/2020	Morgan Stanley	Boost Target	Equal Weight	$148.00 ➝ $157.00	Low
6/29/2020	Mizuho	Boost Target	Neutral	$155.00 ➝ $164.00	Low
6/19/2020	Bank of America	Reiterated Rating	Buy	$180.00	Low
6/17/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$175.00 ➝ $190.00	Low
6/16/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$182.00	High
4/24/2020	Mizuho	Boost Target	Buy	$148.00 ➝ $155.00	Low
4/24/2020	Cfra	Boost Target	Hold	$146.00 ➝ $167.00	Low
4/24/2020	Cantor Fitzgerald	Boost Target	Overweight	$156.00 ➝ $185.00	Low
4/20/2020	UBS Group	Downgrade	Buy ➝ Neutral	$157.00 ➝ $158.00	High
4/19/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low
4/15/2020	Cowen	Boost Target	Outperform	$145.00 ➝ $160.00	Medium
4/9/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$148.00	Low
4/2/2020	Mizuho	Reiterated Rating	Hold	$148.00	Medium
4/2/2020	Morgan Stanley	Lower Target	Overweight ➝ Equal Weight	$150.00 ➝ $148.00	High
3/11/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$168.00	Medium
2/27/2020	Barclays	Initiated Coverage	Overweight		High
2/18/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Low
2/5/2020	Mizuho	Initiated Coverage	Neutral	$148.00	Low
2/3/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$156.00	Medium
12/30/2019	Argus	Boost Target	Buy	$145.00 ➝ $165.00	Low
12/18/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$140.00 ➝ $150.00	High
12/18/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$116.00 ➝ $150.00	High
12/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Low
10/17/2019	UBS Group	Lower Target	Buy	$134.00 ➝ $133.00	Low
10/16/2019	Bank of America	Initiated Coverage	Buy	$133.00	Low
9/10/2019	Bank of America	Set Target	Neutral	$118.00 ➝ $120.00	High
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$135.00	Low
5/1/2019	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$130.00 ➝ $133.00	Low
4/30/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$143.00	Medium
4/23/2019	Edward Jones	Upgrade	Hold ➝ Buy	$117.49	Low
4/22/2019	BMO Capital Markets	Lower Target	Outperform	$130.00	Medium
4/14/2019	Barclays	Reiterated Rating	Buy	$140.00	Low
4/11/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$125.84	Low
3/22/2019	Credit Suisse Group	Set Target	Hold	$121.00	Low
3/21/2019	Bank of America	Set Target	Hold	$129.00	Low
3/20/2019	UBS Group	Initiated Coverage	Buy	$140.00 ➝ $74.51	Low
3/12/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$140.00	Low
2/26/2019	Citigroup	Set Target	Hold	$124.00	Medium
2/8/2019	UBS Group	Lower Target	Average	$107.53 ➝ $100.00	Low
2/4/2019	Cantor Fitzgerald	Reiterated Rating	Buy		Low
1/23/2019	UBS Group	Initiated Coverage	Buy ➝ Buy	$131.00	Low
1/20/2019	Barclays	Reiterated Rating	Buy	$130.00	Low
12/27/2018	Argus	Reiterated Rating	Buy		Medium
12/24/2018	BMO Capital Markets	Boost Target	Outperform	$124.00 ➝ $132.00	Low
12/20/2018	Morgan Stanley	Set Target	Hold	$116.00	High
12/19/2018	BMO Capital Markets	Reiterated Rating	Buy		Low
12/2/2018	Citigroup	Downgrade	Buy ➝ Neutral	$113.00	Low

(Data available from 11/30/2018 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

43 very positive mentions
86 positive mentions
21 negative mentions
6 very negative mentions

Mentions as of

5/4/2023

31 very positive mentions
48 positive mentions
1 negative mentions
7 very negative mentions

Mentions as of

6/3/2023

41 very positive mentions
48 positive mentions
16 negative mentions
5 very negative mentions

Mentions as of

7/3/2023

39 very positive mentions
56 positive mentions
7 negative mentions
2 very negative mentions

Mentions as of

8/2/2023

40 very positive mentions
56 positive mentions
12 negative mentions
6 very negative mentions

Mentions as of

9/1/2023

47 very positive mentions
36 positive mentions
8 negative mentions
6 very negative mentions

Mentions as of

10/1/2023

55 very positive mentions
66 positive mentions
8 negative mentions
21 very negative mentions

Mentions as of

10/31/2023

48 very positive mentions
72 positive mentions
17 negative mentions
8 very negative mentions

Mentions as of

11/30/2023

Current Sentiment

Recent Stories by Sentiment

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $591.04

$586.21

$596.23

50 Day Range

MA: $579.57

$525.10

$619.50

52 Week Range

Now: $591.04

$309.20

$629.97

Volume

5,388,421 shs

Average Volume

3,084,120 shs

Market Capitalization

$561.08 billion

P/E Ratio

107.07

Dividend Yield

0.76%

Beta

0.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and Company?: The following sell-side analysts have issued reports on Eli Lilly and Company in the last twelve months: 22nd Century Group, Inc., 3M, Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LLY.
What is the current price target for Eli Lilly and Company?: 24 Wall Street analysts have set twelve-month price targets for Eli Lilly and Company in the last year. Their average twelve-month price target is $559.08, suggesting a possible downside of 5.1%. Morgan Stanley has the highest price target set, predicting LLY will reach $722.00 in the next twelve months. Societe Generale has the lowest price target set, forecasting a price of $278.00 for Eli Lilly and Company in the next year.
View the latest price targets for LLY.
What is the current consensus analyst rating for Eli Lilly and Company?: Eli Lilly and Company currently has 1 sell rating, 2 hold ratings and 18 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LLY.
What other companies compete with Eli Lilly and Company?: Other companies that are similar to Eli Lilly and Company include Johnson & Johnson, Merck & Co., Inc., AbbVie, Pfizer and Novo Nordisk A/S. Learn More about companies similar to Eli Lilly and Company.
How do I contact Eli Lilly and Company's investor relations team?: Eli Lilly and Company's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is johnson_philip[email protected]. The official website for Eli Lilly and Company is www.lilly.com. Learn More about contacing Eli Lilly and Company investor relations.

Eli Lilly and Company - LLY Stock Price Target and Predictions

Analyst Price Target for LLY

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.57 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and Company?

What is the current price target for Eli Lilly and Company?

What is the current consensus analyst rating for Eli Lilly and Company?

What other companies compete with Eli Lilly and Company?

How do I contact Eli Lilly and Company's investor relations team?